to reduce duplicate discounting and diversion within contract pharmacy arrangements and reforms to ensure these arrangements are targeted exclusively at improving access to medicines for low-income or vulnerable patients of covered entities. Subsequent reports under this paragraph should continue to monitor such issues and be updated as changes are made to the drug discount program under this section. . (g) User fees under the 340B drug discount program Section 340B of the Public Health Service Act ( 42 U.S.C. 256b ), as previously amended, is further amended by adding at the end the following new subsection: (h) User fees (1) In general Subject to paragraph (6), the Secretary shall assess and collect a user fee from covered entities described in subparagraph (L), (M), (N), or (O) of subsection (a)(4). In carrying out this subsection, the Secretary shall not require manufacturers to collect any user fee or to administer the user fee program established under this subsection. (2) Payment A covered entity described in subparagraph (L), (M), (N), or (O) of subsection (a)(4) shall pay to the Secretary a fee assessed under paragraph (1) by such date that is the later of— (A) the date of the certification or recertification of the covered entity, as applicable